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Comparison of Deep Sedation and General Anesthesia
With an Endotracheal Tube for Transcaval
Transcatheter Aortic Valve Replacement: A Pioneering
Institution’s Experience
1
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y
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Objectives: Transcaval transcatheter aortic valve replacement (TC-TAVR) is an alternative approach to transcatheter aortic valve replacement
involving deployment of the bioprosthetic valve via a conduit created from the inferior vena cava to the descending aorta in patients for whom
the traditional transfemoral approach is not feasible. By analyzing the largest known cohort of TC-TAVR patients, the authors wished to compare
hospital length of stay and post-procedure outcomes between patients who underwent the procedure under deep sedation (DS) and patients who
underwent general anesthesia with an endotracheal tube.
Design: Retrospective, single-center study.
Setting: Henry Ford Hospital in Detroit, MI.
Participants: Patients undergoing TC-TAVR from 2015 to 2018.
Measurements and Main Results: Seventy-nine patients were included in the analysis, which consisted of 38 under general anesthesia with an
endotracheal tube and 41 under DS. The sample was divided into a general anesthesia (GA) group and DS group. There were no significant differences in implant success rate or post-procedure outcomes, including in-hospital mortality (p = 0.999) and major vascular complication rate
(p = 0.481), between the two groups. Patients in the GA group stayed a median of 24 hours longer in the intensive care unit (ICU) (p < 0.001)
and one day longer in the hospital (p = 0.046) after the procedure compared to patients in the DS group. The median procedure time was significantly lower (135 minutes) in the DS group compared to the GA group (167 minutes, p < 0.001).
Conclusions: Patients undergoing TC-TAVR under DS had similar postoperative outcomes and shorter post-procedure hospital and ICU lengths
of stay compared to general anesthesia. In the authors’ experience, DS is the preferred anesthetic technique for TC-TAVR.
Ó 2020 Elsevier Inc. All rights reserved.
Key Words: transcaval transcatheter aortic valve replacement; transcatheter aortic valve replacement; deep sedation; general anesthesia; aortic stenosis

TRANSCATHETER AORTIC valve replacement (TAVR)
is a minimally invasive procedure performed to replace the
aortic valve in aortic stenosis. The traditional approach for
1
Address correspondence to Joseph A. Sanders, MD, Department of Anesthesiology, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202.
E-mail address: Jsande11@hfhs.org (J.A. Sanders).

TAVR is to obtain arterial access via the femoral artery; that
is, transfemoral TAVR. However, there is a subgroup of
patients who are not candidates for traditional transfemoral
transcatheter aortic valve replacement (TF-TAVR) due to
small or otherwise inaccessible femoral arteries. Studies have
shown that this subgroup of patients may be as high as 15% of
the population and are often women with small iliofemoral

https://doi.org/10.1053/j.jvca.2020.12.031
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arteries or those with peripheral arterial disease.1,2 In addition,
use of large arterial sheaths poses a risk for major vascular
complications including hemorrhage and rupture.3 Alternative
therapies that also may pose a risk for major vascular complications include transcaval, transaortic, transcarotid, subclavian, and transapical approaches.
Transcaval aortic valve replacement (TC-TAVR) first was
attempted in humans in 2013 at the authors’ institution and,
subsequently, has become an alternative approach for patients
who cannot receive the traditional TAVR.4,5 TC-TAVR has
been shown to be as safe as transcarotid or TF-TAVR.6 The
principle of TC-TAVR is that the retroperitoneal interstitial
hydrostatic pressure exceeds venous pressure, forcing blood
exiting the aorta to return to venous circulation via the aortocaval communication into the inferior vena cava (IVC).4,5
At the authors’ institution, anesthetic management for transfemoral TAVR is achieved using deep sedation (DS). This
approach avoids endotracheal intubation, and employs DS
using various intravenous anesthetics such as propofol, remifentanil, and dexmedetomidine. There are many studies that
show potential benefits of this approach, such as decreased
intensive care unit (ICU) stay, decreased costs, and decreased
time in the hospital.7,8 For TC-TAVR, there are no published
guidelines for optimal anesthetic management. At the authors’
institution, patients have received general anesthesia (GA)
with an endotracheal tube as well as DS.
By examining the largest known single-institution cohort of
TC-TAVR patients, the authors hypothesized that DS was similar to GA with respect to post-procedure outcomes including
implant success, in-hospital mortality, and rates of major vascular complications, and, potentially, is associated with shorter
post-procedure hospital and ICU length of stay.

Methods
The study presented herein was a retrospective, single-center, cohort study performed at Henry Ford Hospital’s main
campus after approval from the institutional review board.
Electronic health record data from patients receiving TCTAVR at Henry Ford Hospital from 2015 to 2018 were
obtained for review via the Epic electronic medical record and
the Society of Thoracic Surgeons (STS)/American College of
Cardiology Transcatheter Valve Therapy Registry. Patients
selected for TC-TAVR included patients with severe, symptomatic aortic valvular heart disease deemed as high or prohibitive surgical risk. A multidisciplinary team of surgeons,
cardiologists, and anesthesiologists had reached a consensus
that these patients likely would benefit from TAVR but would
not be suitable for transfemoral approach due to small or diseased iliofemoral vessels as identified by computed tomography angiography. A balloon-expandable transcatheter heart
valve (Edwards, Irvine, CA) or a self-expandable transcatheter
heart valve (Medtronic, Fridley, MN) was used for TC-TAVR.
The size and choice of valve was decided at a multidisciplinary
meeting. The authors’ approximate distribution for all TAVRs
was 80% balloon expandable and 20% self-expandable.

TC-TAVR involves gaining arterial access by initially
obtaining venous access followed by crossing the retroperitoneal interstitial space by creating an opening between the IVC
and the abdominal aorta. The valve then is deployed through
the IVC aortic conduit up into the aortic valve position. After
deployment, the hole subsequently is closed using a nitinol
occluder device similar to that used in atrial septal defect closure. A preprocedural contrast computed tomography identifies an appropriate caval-aortic crossing trajectory, and is
achieved by means of simultaneous aortography and venography during the procedure. Unlike the transcarotid approach,
the TC-TAVR is fully percutaneous and has favorable
ergonomics.9
The TC-TAVR patient sample was divided into two cohorts:
GA and DS. The GA group was defined as patients who underwent endotracheal intubation with muscle relaxation. The DS
group of patients underwent sedation with spontaneous ventilation. An anesthesiologist was involved in the intraprocedural
care of all TC-TAVR patients.
Via retrospective chart review, it was identified that there
were no specific selection criteria to select the technique of
anesthesia; that is, DS versus GA defined as intubated with an
endotracheal tube. The anesthetic technique was at the discretion of the attending anesthesiologist managing the patient.
The anesthesia technique used was ascertained by chart review
of the preoperative assessment and the intraoperative record.
Patients who underwent DS and then had to be intubated intraprocedurally were excluded from the data analysis.
Patients in the GA group were induced with propofol and
rocuronium and underwent endotracheal intubation followed
by maintenance with isoflurane. Patients were reversed with
sugammadex or neostigmine/glycopyrrolate at the completion
of the procedure and were attempted to be extubated in the
procedure room based on standard extubation criteria at the
discretion of the cardiothoracic anesthesiologist (procedural
success, patient awake, following commands, and hemodynamically stable). Patients in the DS group were sedated with
a combination of propofol, dexmedetomidine, and/or remifentanil to maintain spontaneous ventilation. Patients typically
are unconscious, maintaining spontaneous ventilation via simple facemask with purposeful response to only painful or
repeated stimuli (DS). Patients from both groups who had
hemodynamic instability after the procedure requiring pressor/
inotrope support or those who could not be extubated successfully were admitted to the ICU.
Patient demographic characteristics and data on coexisting
medical comorbidities, including hypertension, diabetes mellitus, chronic lung disease, prior cerebrovascular accidents, prior
myocardial infarctions, prior percutaneous coronary interventions, and prior cardiac surgeries, were collected for each
group. Before the procedure, risk stratification was performed
using the STS risk score. Procedure-specific characteristics
that were analyzed included procedure duration, fluoroscopy
time and dose, and hospital and ICU durations of stay.
Patients were followed up from date of hospital admission
up to hospital discharge. The primary outcomes were hospital
and ICU length, of stay after the procedure. Secondary
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outcomes included procedure duration and rates of implant
success, cardiac arrest, in-hospital ischemic stroke, major vascular complications, and death. Per the STS/American College
of Cardiology Transcatheter Valve Therapy Registry database
definitions, the procedure duration was defined as the time
from initial vascular access attempt to the time that the patient
leaves the room. Implant success was defined as (1) successful
vascular access, delivery, and deployment of the device and
successful retrieval of the delivery system; (2) correct position
of the device in the proper anatomic location; (3) intended performance of the prosthetic heart valve (aortic valve area >1.2
cm2 and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, without moderate or severe prosthetic valve aortic
regurgitation); and (4) only one valve implanted in the proper
anatomic location. Major vascular complications were defined
by aortic dissection or rupture, access-related vascular injury
leading to life-threatening bleeding, or distal embolization
resulting in irreversible end-organ damage.
Continuous variables were summarized in mean and standard deviation, or median and interquartile range, and compared by using Student t test or Mann-Whitney test.
Categorical variables were summarized in frequency and proportion and compared by using Pearson chi-square test or
Fisher exact test if the expected value in any cell was <5. A p
value < 0.05 was considered to be statistically significant. All
statistical analysis was performed use R software version 3.5.2
(R Foundation for Statistical Computing, Vienna, Austria;
https://www.R-project.org/).
Results
A total of 83 patients underwent TC-TAVR at Henry Ford
Hospital between 2015 and 2018. Thirty-eight belonged to the
general GA group and 41 belonged to the DS group. Four
patients converted from DS to GA during the procedure and
were excluded from the study.
There was a considerable variation in proportion of cases
over the years, reflective of procedural experience and learning
curve. In 2015, 25% of the cases were performed under DS;
this increased to 33% in 2016, 75% in 2017, and 100% in
2018.
Patient demographics, including age and sex, were comparable between the GA and DS groups (Table 1). There was no
significant difference in median body mass index between the
GA and DS groups. Prevalence of medical comorbidities,
including diabetes mellitus, hypertension, and chronic lung
disease, were not significantly different between the groups.
Rates of prior myocardial infarction, stroke, and history of percutaneous coronary intervention or coronary artery bypass
graft were similar between the GA and DS groups (Table 1).
The overall median STS risk score was 5.58, indicating an
intermediatehigh-risk patient population. There were no statistical differences in STS risk scores, ejection fraction, or aortic valve parameters (peak velocity, valve area, and gradient)
between the GA and DS groups (Table 1).
Patients undergoing GA had significantly longer procedure
durations (167 minutes v 135 minutes, p = 0.003). However,
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Table 1
Patient Characteristics*
Characteristic

GA (n = 38)

DS (n = 41)

p Value

Age
Male sex
BMI
Diabetes
Hypertension
Chronic lung disease
Previous MI
Previous stroke
Previous PCI
Previous CABG
STS risk score
Ejection fraction
Aortic valve area
Aortic peak velocity
Aortic peak gradient
Aortic mean gradient

81 (74-86)
14 (36.8)
25.8 (22.9-30.4)
16 (42.1)
36 (94.7)
9 (23.7)
14 (36.8)
2 (5.3)
15 (39.5)
16 (42.1)
7.1 (4.3-10.4)
58 (42, 63)
0.7 (0.6-0.84)
3.8 (3.25, 4.32)
56 (42.5-76.5)
38.5 (24.5-47.5)

80 (73-86)
22 (53.7)
24.7 (21.2-27.8)
20 (48.8)
35 (85.4%)
10 (24.4)
12 (29.3)
7 (17.1)
22 (53.7)
10 (24.4)
4.7 (3.1-7.9)
60 (55, 67)
0.69 (0.53-0.82)
3.9 (3.6, 4.4)
64 (54.5-78)
40 (30.5-45.5)

0.476
0.203
0.261
0.712
0.314
0.513
0.634
0.195
0.300
0.151
0.053
0.056
0.690
0.402
0.198
0.345

Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft;
DS, deep sedation; GA, general anesthesia; MI, myocardial infarction; PCI,
percutaneous coronary intervention; STS, Society of Thoracic Surgeons.
* Normally distributed data shown as mean § standard deviation, non-normally distributed data as median (25th-75th percentile), and categorical
data as n (% of group).

there were no significant differences in median fluoroscopy
time (p = 0.566), fluoroscopy dose (p = 0.084), or contrast volume (p = 0.462; Table 2).
The overall implant success rate was 97.5%, with no significant differences in success rates between the GA and DS
groups (97.4% v 97.6%, respectively, p = 0.999). Patient follow-up after the procedure revealed significantly longer ICU
and hospital lengths of stay in the GA group. On average,
patients who underwent GA stayed one day longer in the hospital and 24 hours longer in the ICU than patients who underwent DS (p = 0.046 and p < 0.001, respectively). There were
no significant differences in rates of complications including
cardiac arrest, ischemic stroke, or major vascular complications between the GA and DS groups after the procedure
(Table 3).
The in-hospital mortality rate in patients who underwent the
TC-TAVR procedure was 1.3% (one patient of 79). There was

Table 2
Procedural Data*
Procedural Data

GA (n = 38)

DS (n = 41)

p Value

Implant success
Fluoroscopy time (s)
Fluoroscopy dose kerma
Contrast volume
Procedure time (min)

37 (97.4)
42 (39-50)
805 (605-1106)
127 (91-149)
167 (144-200)

40 (97.6)
41 (36-50)
728 (468-951)
131 (101-160)
135 (114-164)

0.999
0.566
0.084
0.462
0.003z

Abbreviations: DS, deep sedation; GA, general anesthesia.
* Normally distributed data shown as mean § standard deviation, non-normally distributed data as median (25th-75th percentile), and categorical
data as n (% of group)
z p < 0.01.
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Table 3
Outcomes*
Outcome

GA (n = 38)

DS (n = 41)

p Value

Major vascular complication
Cardiac arrest
Ischemic stroke
Length of stay ICU (h)
Length of stay hospital (d)
In-hospital mortality

1 (2.6)
3 (7.9)
0 (0)
24 (18-42)
5 (4-6)
0 (0)

0 (0)
1 (2.4)
1 (2.4)
0 (0-16)
4 (3-6)
1 (2.4)

0.481
0.347
0.999
< 0.001z
0.046y
0.999

Abbreviations: DS, deep sedation; GA, general anesthesia; ICU, intensive care
unit.
* Normally distributed data shown as mean § standard deviation, non-normally distributed data as median (25th-75th percentile), and categorical
data as n (% of group).
y
p < 0.05.
z p < 0.01.

no significant difference in in-hospital mortality between the
two groups (p = 0.999; Table 3).
Although not part of the study analysis, four patients converted from DS to GA. Reasons for conversion were obtained
from chart review. One of the patients was intubated due to
worsening hypercapnia and one was difficult to sedate due to
altered mental status in the setting of acute liver failure. The
other two patients required conversion to GA due to procedure-related concerns including need to perform a transesophageal echocardiogram and due to the cardiologist’s
preference.
Discussion
The authors’ institution’s experience suggests that DS could
be a viable option in patients undergoing transcaval TAVR. In
this study, patients receiving DS for TC-TAVR had similar
rates of implant success and postoperative outcomes to
patients receiving GA with an endotracheal tube. The authors
found that ICU length of stay and hospital length of stay were
significantly lower in the DS group compared to the GA group.
The length of the procedure was also significantly lower in the
DS group compared to the GA group. This study suggested
that use of DS may provide a more efficient use of hospital
and ICU time in centers performing TC-TAVR.
The first TC-TAVR procedure was performed at Henry Ford
Hospital in 2013 and published in 2014.4 Due to the novel
nature of the procedure and learning curve, all the initial TCTAVRs were performed at the authors’ institution using GA
with an endotracheal tube. The decision to secure the airway
was based on lack of experience with caval-aortic puncture
and anticipation of hemodynamic instability. Initially, nearly
all patients were admitted to the ICU after the procedure for
possible risk of major vascular complication. However, by the
end of 2014, due to improving operator experience, high
implant success rates (>95%), and low rates of major vascular
complications, the authors’ institution started performing these
procedures under DS. As more cardiac anesthesiologists
became familiar with the procedure, a higher proportion of

cases were being performed under DS. By 2018, nearly 100%
of TC-TAVRs at the authors’ institution were being performed
under DS. To date, there is a lack of literature guiding anesthetic technique for transcaval TAVRs. To provide more
objective data, the authors decided to perform this study and
analyze data from 2015 to 2018 to help provide evidence to
select the mode of anesthesia for these procedures.
Based on the authors’ analysis, the median procedure duration was 32 minutes longer in the GA group than the DS group,
and this was statistically significant (p = 0.003). Although this
duration did not include time for induction/intubation or time
for reaching appropriate depth of sedation, this duration did
include time taken for emergence and attempt at extubation.
There was no significant difference in overall median procedure durations on a year-to-year basis (2015, 2016, 2017, and
2018). This likely suggests that the role of learning curve and
operator experience in procedure duration after 2015 was not
significant. The authors believe that the significant difference
in procedure duration between the groups probably can be
explained by the time taken for emergence from GA, including
muscle relaxant reversal and time taken for extubation assessment and, finally, the extubation attempt, if possible. The
median patient age being 80 likely accounted for longer durations of emergence and role of multiple comorbidities including chronic lung disease. The authors’ center uses a
combination of propofol, dexmedetomidine, and/or remifentanil for DS for TC-TAVRs. By using these agents with a relatively low context-sensitive half-time, the time for emergence
from sedation is considerably lower compared to agents such
as midazolam and fentanyl.10
The median ICU duration of the GA group was 24 hours
longer than that of the DS group (p < 0.001), and the median
hospital length of stay in the GA group was one day longer
(p = 0.046). This significant result was because 33 of 38 GA
patients required an ICU stay, whereas only 14 of 41 DS
patients were admitted to the ICU. Intubation rather than sedation in this frail population requiring TC-TAVRs is associated
with greater hemodynamic instability leading to ICU stay. An
observational study by Dehedin et al. in patients undergoing
TF-TAVR found that patients receiving GA had greater hemodynamic instability and intraoperative requirement of catecholamines.11 In addition, 23.7% of these patients had chronic
lung disease (Table 1), which is associated with extubation
failure,12 leading to prolonged ICU and hospital length of stay.
A retrospective observational cohort study by Abawi et al.
found that use of GA in the nontransfemoral TAVR group was
associated with prolonged in-hospital stay, which could be
related to increased rates of postoperative delirium.13
Although there are numerous published reports comparing
sedation with GA for transfemoral TAVRs, the type of anesthetic often is defined poorly using terms such as monitored
anesthesia care, conscious sedation, or moderate sedation
without a clear definition. Going forward, it is critical to define
the level of sedation as clearly as possible as the role of anesthesiologists for TAVR is continually evolving.14 The largest
observational study to date by Hyman et al. compared conscious sedation versus GA for transfemoral TAVR and found
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statistically significantly shorter lengths of stay and lower mortality in the conscious sedation group compared to the GA
group.7 This study was observational and suggested the relative safety of conscious sedation, but better-designed studies
are needed to show the superiority of conscious sedation.
The femoral arterial access is still the preferred approach for
TAVR worldwide. However, in the unique high-risk population of patients who are not candidates for femoral access, the
authors have seen that the transcaval approach is a viable alternative, with an overall implant success rate of 97.5% and inhospital mortality of 1.3%, which were not significantly different between the GA and DS groups. Paone et al. performed a
retrospective review to compare transfemoral, transcarotid,
and transcaval access for TAVR. The authors found no difference in 30-day/in-hospital and one-year survival.6
Of the four patients who converted from DS to GA, two
patients converted secondary to patient-related factors including worsening hypercapnia in a patient with chronic obstructive pulmonary disease and obstructive sleep apnea, and
altered mental status in a patient with acute liver failure and
hepatic encephalopathy, which made it difficult to make any
conclusions. Larger studies with a more substantial cohort of
patients should examine if certain patient characteristics could
predict the need for GA, but this may not be possible as TCTAVR is a very uncommon procedure. Although not specific
for DS, there is evidence that a multidisciplinary team and
review of baseline patient characteristics can help with deciding on minimalist versus GA pathways.15 However, there also
is evidence that baseline patient characteristics for patients
undergoing TF-TAVR with the minimalist technique are not
predictive of intraoperative morbidity, which likely applies to
TC-TAVR as well.16 Therefore, the group believes that despite
evidence TAVR can be done without an anesthesiologist, there
should always be an anesthesiologist present for any TAVR,
especially TC-TAVR, as procedural complications can
occur.17,18
Conversion at the cardiologist’s request and need for transesophageal echocardiography (TEE) were procedure-related
factors responsible for conversion in the remaining two
patients. Hahn et al. explained that although TEE can be valuable in intraprocedural confirmation of landing zone morphology and valve positioning, reports from experienced, highvolume sites stated that intraprocedural TEE imaging may not
be necessary for safe placement of a transcatheter heart
valve.19 In a review of imaging in TAVR procedures, Bleakley
et al. stated that the shift away from general anesthesia has led
to fewer patients having TEE-guided TAVR, but this did not
have any impact on outcomes.20
It is important to interpret this study in the context of the
limitations. Despite being the largest cohort of patients receiving TC-TAVR, this was only a single-center study. Being a retrospective review, selection criteria for GA versus DS is
typically anesthesia providerdependent and preference for
DS has evolved over time and experience. Although there was
no significant difference in body mass index between the
groups, only 20% of the sample population was obese. The
authors understand that centers with a high proportion of
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patients who are obese may prefer GA due to greater risk of
airway obstruction and difficult airway. In addition, although
it was clear that all patients in DS group did not undergo endotracheal intubation and all patients in the GA group underwent
endotracheal intubation, the precise anesthetic depth of each
patient in the DS group was not standardized. Multiple cardiac
anesthesiologists have been involved in these procedures, and
no protocol/guidelines have been used for anesthetizing these
patients prior to this study.
In conclusion, this single-center retrospective study suggested that DS had similar postoperative outcomes and shorter
hospital and ICU lengths of stay after the procedure compared
to general anesthesia. The authors strongly believe that DS
should be used whenever possible, since quicker time to hospital discharge translates to more efficient use of ICU and hospital time and resources. However, the decision to use sedation
for TC-TAVRs should be based on operator and institutional
experience. Perhaps a minimalist approach; that is, conscious
sedation, is possible for TC-TAVR, but this is yet to be proven.
The authors believe a strong multidisciplinary approach (surgeon, cardiologist, and cardiac anesthesiologist present) is paramount for delivering a safe anesthetic and achieving positive
results in this challenging patient population.
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